Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oragenics

3.49
+0.03000.87%
Volume:191.10K
Turnover:692.13K
Market Cap:2.50M
PE:-0.12
High:3.88
Open:3.56
Low:3.31
Close:3.46
Loading ...

Major Shareholder Odyssey Health Sells Oragenics Stock!

TIPRANKS
·
19 Jun

Odyssey Health, Inc. Reports Disposal of Common Shares of Oragenics Inc

Reuters
·
19 Jun

Oragenics Inc. Files Initial Statement of Beneficial Ownership Naming Odyssey Health, Inc. as 10% Owner

Reuters
·
17 Jun

Top Premarket Decliners

MT Newswires Live
·
04 Jun

Amex Halt Add Info Lst 6.790000

THOMSON REUTERS
·
03 Jun

Oragenics trading halted, volatility trading pause

TIPRANKS
·
03 Jun

Amex Halt Add Info Lst 5.960000

THOMSON REUTERS
·
03 Jun

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Benzinga
·
02 Jun

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

THOMSON REUTERS
·
28 May

Oragenics Hosts Neurotrauma Medicine Webinar Presentation

TIPRANKS
·
21 May

Oragenics, Inc. Announces Approval to Initiate Phase Ii Concussion Drug Trial in Australia

THOMSON REUTERS
·
13 May

BRIEF-Oragenics Announces Health And Disability Ethics Committee Submission

Reuters
·
09 Apr

Oragenics announces HDEC submission for Phase II concussion trial

TIPRANKS
·
09 Apr

Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial

GlobeNewswire
·
09 Apr

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

GlobeNewswire
·
08 Apr

BRIEF-Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress

Reuters
·
27 Mar

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

THOMSON REUTERS
·
27 Mar

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

GlobeNewswire
·
27 Mar

Oragenics submits IB for Phase II clinical trial of ONP-002 in mTBI

TIPRANKS
·
06 Mar

Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

GlobeNewswire
·
06 Mar